Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Anaplastic lymphoma kinase as a therapeutic target.

Kruczynski A, Delsol G, Laurent C, Brousset P, Lamant L.

Expert Opin Ther Targets. 2012 Nov;16(11):1127-38. doi: 10.1517/14728222.2012.719498. Epub 2012 Sep 24. Review.

PMID:
22998583
2.

Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.

Roskoski R Jr.

Pharmacol Res. 2013 Feb;68(1):68-94. doi: 10.1016/j.phrs.2012.11.007. Epub 2012 Nov 28. Review.

PMID:
23201355
3.

Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.

Mesaros EF, Ott GR, Dorsey BD.

Expert Opin Ther Pat. 2014 Apr;24(4):417-42. doi: 10.1517/13543776.2014.877890. Epub 2014 Jan 30. Review.

PMID:
24476492
4.

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B.

Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Review.

5.

Inhibitors of the anaplastic lymphoma kinase.

Mologni L.

Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22. Review.

PMID:
22612599
6.

Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date.

Lowe EJ, Lim MS.

Paediatr Drugs. 2013 Jun;15(3):163-9. doi: 10.1007/s40272-013-0027-3.

7.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J.

Cancer Res. 2008 May 1;68(9):3389-95. doi: 10.1158/0008-5472.CAN-07-6186.

8.

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA.

Mol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27.

9.

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Katayama R, Lovly CM, Shaw AT.

Clin Cancer Res. 2015 May 15;21(10):2227-35. doi: 10.1158/1078-0432.CCR-14-2791. Review.

PMID:
25979929
10.

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SW.

Expert Rev Anticancer Ther. 2009 Mar;9(3):331-56. doi: 10.1586/14737140.9.3.331. Review.

11.

The ALK gene, an attractive target for inhibitor development.

Tartari CJ, Scapozza L, Gambacorti-Passerini C.

Curr Top Med Chem. 2011;11(11):1406-19. Review.

PMID:
21513493
12.

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

af Gennäs GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J.

ChemMedChem. 2011 Sep 5;6(9):1680-92. doi: 10.1002/cmdc.201100168. Epub 2011 Jun 30.

PMID:
21721129
13.

The battle against ALK resistance: successes and setbacks.

Voena C, Chiarle R.

Expert Opin Investig Drugs. 2012 Dec;21(12):1751-4. doi: 10.1517/13543784.2012.717930. Epub 2012 Aug 25.

PMID:
22920921
14.

Inhibitors of anaplastic lymphoma kinase: a patent review.

Milkiewicz KL, Ott GR.

Expert Opin Ther Pat. 2010 Dec;20(12):1653-81. doi: 10.1517/13543776.2010.527332. Epub 2010 Oct 20. Review.

PMID:
20961208
15.

Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.

Yi ES, Chung JH, Kulig K, Kerr KM.

Mol Diagn Ther. 2012 Jun 1;16(3):143-50. doi: 10.2165/11632830-000000000-00000. Review.

PMID:
22506598
16.

The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.

Roskoski R Jr.

Expert Opin Drug Discov. 2013 Sep;8(9):1165-79. doi: 10.1517/17460441.2013.813015. Epub 2013 Jun 28. Review.

PMID:
23805942
17.

ALK-immunoreactive neoplasms.

Minoo P, Wang HY.

Int J Clin Exp Pathol. 2012;5(5):397-410. Epub 2012 May 23. Review.

18.

The anaplastic lymphoma kinase as an oncogene in solid tumors.

Voena C, Peola S, Chiarle R.

Front Biosci (Schol Ed). 2015 Jun 1;7:269-82. Review.

PMID:
25961702
19.

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.

Li R, Morris SW.

Med Res Rev. 2008 May;28(3):372-412. Review.

PMID:
17694547
20.

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.

Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Review.

PMID:
23472711
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk